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ABSTRACT
Vaccine licensure requires a very high safety standard 
and vaccines routinely used are very safe. Vaccine safety 
monitoring prelicensure and postlicensure enables 
continual assessment to ensure the benefits outweigh the 
risks and, when safety problems arise, they are quickly 
identified, characterised and further problems prevented 
when possible. We review five vaccine safety case studies: 
(1) dengue vaccine and enhanced dengue disease, (2) 
pandemic influenza vaccine and narcolepsy, (3) rotavirus 
vaccine and intussusception, (4) human papillomavirus 
vaccine and postural orthostatic tachycardia syndrome and 
complex regional pain syndrome, and (5) RTS,S/adjuvant 
system 01 malaria vaccine and meningitis, cerebral 
malaria, female mortality and rebound severe malaria. 
These case studies were selected because they are recent 
and varied in the vaccine safety challenges they elucidate. 
Bringing these case studies together, we develop lessons 
learned that can be useful for addressing some of the 
potential safety issues that will inevitably arise with new 
vaccines.
INTRODUCTION
Vaccines are held to a very high safety 
standard as they are given to healthy individ-
uals to prevent rather than to treat disease, 
often administered to a large proportion of 
the population, and their use is supported by 
governments and health authorities. Vaccines 
routinely used are very safe and, while adverse 
reactions do occur, serious adverse reactions 
are very rare. Vaccine safety is monitored 
throughout the product life cycle—from 
research and development through postlicen-
sure surveillance. This ensures that routinely 
used vaccines are very safe, the benefits 
outweigh the risks in the populations for 
which they are indicated and safety problems 
if they arise are quickly identified, character-
ised and further problems prevented when 
possible.
In this paper, we review five vaccine safety 
case studies (box 1):
1. Dengue vaccine and enhanced disease.
2. Pandemic influenza vaccine and narcolep-
sy.
3. Rotavirus vaccine and intussusception.
4. Human papillomavirus (HPV) vaccine and 
postural orthostatic tachycardia syndrome 
(POTS) and complex regional pain syn-
drome (CRPS).
5. RTS,S/AS01 malaria vaccine and meningi-
tis, cerebral malaria, female mortality and 
rebound severe malaria.
For each of these case studies, we review the 
safety issues that have been identified, poten-
tial biological mechanisms, epidemiological 
data, and finally, conclusions about causality 
and areas for future research. These case 
studies were selected because they are recent 
and varied in the vaccine safety challenges 
they elucidate. Bringing these case studies 
together, we develop lessons learnt that can 
be useful for addressing some of the potential 
safety issues that will inevitably arise with new 
vaccines.
DENGUE VACCINE AND ENHANCED DENGUE 
DISEASE
Dengue poses a significant public health 
problem in the tropics and subtropics with 
as many as 390 million infections annually.1 
After decades of research, the world’s first 
Summary box
 ► Adverse events following immunization that are rare, 
happen in subpopulations, and have delayed onset 
are monitored post- licensure.
 ► Vaccine adverse reactions can be related to 
genomics.
 ► There are opportunities for additional research to 
fully define the safety profile of vaccines.
 ► Unanswered safety questions and real safety prob-
lems can undermine public confidence in vaccines.
 ► Transparent and timely communication about ad-
verse events following immunization is crucial to 
maintaining public trust.
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dengue vaccine, chimeric yellow fever- dengue tetrav-
alent dengue vaccine (CYD- TDV) (Dengvaxia), devel-
oped by Sanofi Pasteur, was licensed in 2015.2 CYD- TDV 
is a live attenuated recombinant tetravalent vaccine that 
was evaluated in phase 3 efficacy trials with a 3- dose 0, 6 
and 12 months schedule.3 Results from a comprehensive 
phase 3 clinical trial programme indicated that protec-
tive efficacy varied according to serostatus prior to vacci-
nation and serotype.4 Vaccine- induced immunogenicity 
was not predictive of protective clinical efficacy, and no 
immune correlates (for protection or enhancing disease) 
were established.4
In the phase 3 trial, excess hospitalisations for dengue 
were observed among vaccine recipients 2–5 years of age. 
Precise risk estimates according to dengue serostatus 
prior to vaccination could not be ascertained because 
of the limited numbers of samples collected at baseline. 
A post hoc analysis of safety and efficacy used a novel 
dengue anti- non- structural protein 1 (NS1) IgG ELISA 
on samples from month 13 to retrospectively infer base-
line serostatus. These analyses showed that in seropositive 
trial participants aged 9–16 years, in the 66 months after 
administration of the first vaccine dose, the vaccine was 
protective. HRs, comparing vaccinated to placebo recip-
ients, for hospitalised virologically confirmed dengue 
(VCD) and severe VCD, were 0.21 (95% CI 0.14 to 0.31) 
and 0.16 (95% CI 0.07 to 0.37), respectively. However, 
in seronegative participants aged 9–16 years, vaccinees 
had an increased risk of hospitalised and severe dengue, 
with corresponding HRs of 1.41 (95% CI 0.74 to 2.68) 
and 2.44 (95% CI 0.47 to 12.56), respectively.5 A plau-
sible hypothesis for these findings is that the vaccine acts 
as a ‘silent infection’, so that the first natural infection 
in seronegative recipients is then ‘secondary- like’, with 
an associated increased risk of severe disease, whereas 
in seropositive recipients the first natural infection after 
vaccination is ‘tertiary- like’, which is not associated with a 
higher risk of severe disease.6 In December 2017, Global 
Advisory Committee on Vaccine Safety (GACVS) recom-
mended that Dengvaxia should only be administered to 
individuals who had been previously infected with wild 
dengue virus.7 Based on WHO’s Strategic Advisory Group 
of Experts (SAGE) recommendations, WHO’s posi-
tion published in 2018 is that for countries considering 
Dengvaxia vaccination as part of their dengue control 
programme, a prevaccination screening strategy, in 
which only dengue- seropositive persons are vaccinated, 
is recommended. 8
Implementing a prevaccination screening strategy 
poses major challenges, including the logistics of adminis-
tering a test prior to vaccination, and the additional costs. 
Also, because serological tests are likely to be affected 
by cross- reaction with other flaviviruses, it is likely to be 
difficult to develop highly specific and sensitive tests for 
prior dengue infection. In a high seroprevalence area, 
a test with a very high sensitivity is required, to identify 
most who would benefit from the vaccine, whereas in a 
low seroprevalence area, very high specificity is the most 
important feature to ensure that those at risk from vacci-
nation are excluded from vaccination.8
Lessons learnt from the first licensed dengue vaccine for 
second-generation dengue vaccines
Causality conclusions and areas for future research
Box 1 Summary of case study elements and key lessons
Dengue vaccine and enhanced dengue disease
Dengvaxia was protective for seropositive vaccinees; seronegative 
vaccinees had an increased risk of hospitalisation and severe dengue. 
Recommendations for vaccination only for dengue- seropositive 
people.
Key lessons: Need more understanding of impact of natural disease 
on vaccines.
Pandemic influenza vaccine and narcolepsy
Small but significant increase in narcolepsy following one adjuvanted 
pandemic influenza vaccine. Pandemrix in Sweden, Finland, and UK 
(various rates, highest 1:16 000); the Sleep Apnoea Monitoring with 
Non- Invasive Applications study (1:18 400).
Key lessons: Postlicensure studies in large populations with different 
genetic backgrounds is important. Timing of vaccination during an 
outbreak may be important.
Rotavirus vaccine and intussusception
RotaShield was the first rotavirus vaccine on the market with 
intussusception rates of 1:10 000 (postlicensure). Concerns of higher 
risk if given before 3 months led to age restriction; risk–benefit 
analysis led to discarding restriction. RotaShield was eventually pulled 
from market.
RotaTeq and Rotarix, next on the market, underwent large clinical 
trials with intussusception rates 1-5:100 000 in high- income and 
middle- income countries; Rotarix showed no elevated risks in low- 
income and middle- income country (no data from RotaTeq).
Key lessons: Postlicensure studies in large populations are essential.
Human papillomavirus vaccine and postural orthostatic 
tachycardia syndrome and complex regional pain syndrome
Concerns over complex regional pain syndrome and postural 
orthostatic tachycardia syndrome following the human papillomavirus 
vaccines on the market, Cervarix, Gardasil and Gardasil-9, led to lower 
coverage, confidence and some loss of country recommendations. 
Vaccine adverse event reporting system, European Medical Agency, 
Global Advisory Committee on Vaccine Safety and AAS and large- scale 
studies found no signals or patterns.
Key lessons: Postlicensure studies in large populations are essential 
and effective communication about safety is vital
RTS,S/adjuvant system 1 malaria vaccine and serious adverse 
events
 ► Exploratory analyses in phase 3 trial showed.
 ► Meningitis: increase risk of meningitis in two trial sites in one age 
group; regarded as potential signal.
 ► Cerebral malaria: increased in vaccinees versus controls.
 ► Mortality: increased mortality in vaccinated girls.
 ► Malaria: group receiving only three doses, higher severe malaria 
rate after 18 months versus controls, but effect ameliorated by 
booster dose at 18 months.
Key lessons: Postlicensure studies in large populations are essential 
to address potential safety signals from Phase 3 trials. Need for 
continuation of vaccine trials beyond initial demonstration of efficacy. 
If booster doses may be necessary, these should be built into the 
design of phase 3 trials.
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A comprehensive risk management strategy and 
enhanced communication at the introduction of any 
new vaccine is critical to avoid false expectations and 
maintain vaccine confidence. This was particularly 
the case for Dengvaxia, as there were some indica-
tions and theoretical concerns about disease enhance-
ment (antibody dependent enhancement can occur 
with dengue disease) when SAGE first made recom-
mendations, before the manufacturer had conducted 
the postlicensure analyses, which consolidated the 
previous theoretical concerns and led to revised 
SAGE recommendations. There are also important 
lessons to be learnt for clinical development of 
second- generation live attenuated dengue vaccines 
(now in phase 3 trials).9 Until a surrogate or correlate 
of protection or risk is established, efficacy trials of 
dengue vaccines will need to be conducted based on 
a clinical endpoint. The licensure of the first dengue 
vaccine in several countries, though not necessarily 
approved for use by national public health agencies, 
and sponsor- requested label revision in response to a 
safety finding introduces additional complexities to 
the design and site selection for second- generation 
vaccine development and will require close consul-
tation with national regulatory authorities. Dengue 
serostatus at baseline remains a critical variable, and 
safety and efficacy by serostatus should be presented 
in stratified analyses. Active surveillance used to assess 
efficacy against all dengue disease and severe dengue 
disease should be in place for at least 3, and prefer-
ably 5, years after the last vaccine dose. Immunoge-
nicity and efficacy results should be interpreted in the 
context of potential transient immunity against the 
other serotypes that could wane over time and be asso-
ciated with enhanced disease.
PANDEMIC INFLUENZA VACCINE AND NARCOLEPSY
In 2009, the A(H1N1) pandemic influenza virus (A/
H1N1pdm09) rapidly spread globally starting from 
Mexico.10 As part of a WHO coordinated pandemic 
mitigation plan, manufacturers developed several 
monovalent adjuvanted influenza vaccines to increase 
immunogenicity and spare doses.11 Pandemrix, an 
Adjuvant System 03 (AS03) adjuvanted vaccine, 
was available primarily in Europe. Approximately 
31 million doses were administered to populations in 
Finland, France, Germany, Ireland, Norway, Sweden 
and UK. A similar AS03 adjuvanted vaccine, Arepanrix, 
was primarily available in Canada. Another pandemic 
vaccine, Focetria, an MF59 adjuvanted vaccine, was 
used in Europe, with approximately 6.5 million doses 
globally, mainly administered to populations in Italy, 
Netherlands and Spain.
In August 2010, the Swedish Medical Products Agency 
announced a possible increased risk of narcolepsy, a rare 
chronic sleep disorder, following Pandemrix vaccina-
tion. Soon thereafter, authorities in Finland confirmed a 
similar signal.12 Both countries had offered Pandemrix to 
more than half of their population and coverage was up 
to 80% among school- aged children.
After the initial safety signals in Sweden and Finland, 
the European Medical Agency (EMA) commissioned 
a signal validation study via the European Centre for 
Disease Prevention and Control and the Vaccine Adverse 
Events Monitoring and Communication consortium; a 
case–control approach was used.13 Several other epidemi-
ological studies, including registry- based linkage studies 
in Finland14and Sweden15and self- controlled case series 
studies in the UK,16 were conducted to evaluate the associ-
ation in Europe. Most of these studies indicated significant 
although small absolute risk associated with Pandemrix 
vaccination, translating at the highest to an attributable 
risk of one per 16 000 vaccinated in the susceptible age 
group. In Canada, a case–control study was carried out, 
which found a smaller risk for Arepanrix, that is, one per 
million vaccinated.17 Also, the US CDC commissioned 
a global case control study, the Sleep Apnoea Moni-
toring with Non- Invasive Applications (SOMNIA), in 13 
different study sites in 9 countries.18 It did not find an 
increased risk for the MF59 adjuvanted vaccine Focetria 
or the AS03 adjuvanted Arepanrix vaccine. Due to limited 
sample size in the population at risk, the SOMNIA results 
remain inconclusive for Pandemrix. A systematic review 
and meta- analysis of the published studies was conducted 
by Sarkanen et al, which demonstrated a 5- fold to 14- fold 
increased risk in children and adolescents and a 2- fold 
to 7- fold increased risk in adults of narcolepsy following 
receipt of the Pandemrix vaccine, and an attributable 
risk of 1 per 18 400 vaccinated. The risk has remained 
elevated for 24 months in the susceptible age groups in 
those countries where follow- up studies were done, that 
is, Sweden, Finland and the UK.19
Understanding the pathogenesis of the vaccination- 
associated narcolepsy would be of particular importance 
for future pandemic vaccination strategies. Narcolepsy 
is likely to be immune- mediated in view of the associ-
ation of the disease with the HLA- DQB1*06: 02 haplo-
type.20 In the case of vaccination associated narcolepsy; 
however, there is still scarce evidence of an autoimmune 
process.
In addition, there is growing evidence for an aetiolog-
ical role of natural influenza viral infection, as suggested 
by the peak of narcolepsy observed in China21 and Taiwan 
following the A/H1N109 outbreak in non- vaccinated 
populations.22 During the 2009 pandemic, with the delay 
in the availability vaccines, there was considerable circu-
lation of the pandemic virus in some countries before 
the vaccine was introduced. Thus, it was extremely diffi-
cult to sort out whether many of the immunised subjects 
had previously been infected with the wild- type H1N1 
pandemic strain, and particularly in those vaccinees 
that ultimately developed narcolepsy. It should be noted 
that in Nordic European countries, the pandemic peak 
overlapped or immediately preceded vaccine implemen-
tation.23 In Norway, serological studies indicated that 
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vaccination of school- aged children peaked shortly after 
the peak of disease24 (figure 1).
It was hypothesised that in some rare patients infected 
by H1N1/09 influenza, viruses may migrate through 
the olfactory pathway to the hypothalamus and infect 
hypocretin producing neurons. By itself this may cause 
some neuronal damage, likely amplified by natural CD8 
(cluster of differentiation 8) responses to viral antigens. 
The administration of a strongly adjuvanted influenza 
vaccine at the time or soon after infection could consid-
erably amplify the CD8 response and its pathogenicity 
(figure 2).25 Timing of vaccination in relation to the 
outbreak may be critical.
Causality conclusion and areas for future research
At present, the association between narcolepsy and 
Pandemrix vaccination has been well established.19 The 
exact mechanism of causality, that is, what actually causes 
the damage to hypocretin neurons, is not well understood. 
In the Nordic countries, where approximately 2000 vacci-
nated persons are estimated to have been permanently 
affected, the interpretation is that Pandemrix contributed 
Figure 1 Kinetics of 2009 pH1N1 influenza outbreak and vaccination coverage in Norway.
Figure 2 The two- hit hypothesis—a possible mechanism for an enhanced risk for narcolepsy following 2009 pH1N1.
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to the onset of narcolepsy, but that other factors also 
played a role. This interpretation has also been accepted 
by the authorities in charge of vaccine injury compensa-
tion programmes in these countries, but not necessarily 
elsewhere.26 It also has been agreed that such a rare 
event would not have been detected a priori in phase 3 
human clinical trials. The handling of this incident by 
scientists, medical authorities, and media have resulted 
in a significant drop in influenza vaccination coverage 
among children and distrust in authorities in charge of 
routine vaccination programmes in the most affected 
countries. As of 2020, there is no Pandemrix vaccine in 
use. The adjuvant AS03, however, has been stockpiled for 
future pandemic use, and now forms part of the scientific 
development of at least one vaccine candidate against 
COVID-19. It is evident that there will be future influenza 
and other pandemics; in that light it is important that 
research be continued to better understand the possible 
biological mechanisms of what happened.27
ROTAVIRUS VACCINATION AND INTUSSUSCEPTION
In 1999, the first licensed rotavirus vaccine, RotaShield 
(Wyeth), was withdrawn from the US market (about 14 
months after it was licensed) shortly after its introduction 
because it was associated with intussusception at an esti-
mated rate of 1 case per 10 000 vaccinated infants.,2829,30 
While the prelicensure trials with ~10 000 total subjects 
were unlikely to have identified this risk because of power 
limitations for this sample size, intussusception was listed 
as a potential adverse event because of a few reported cases 
during the prelicensure clinical trials and careful postli-
censure monitoring was conducted.3132 Because of the 
RotaShield experience, the next generation of live- oral 
rotavirus vaccines—RotaTeq (Merck, West Point, Penn-
sylvania, USA) and Rotarix (GlaxoSmithKline, Rixensart, 
Belgium)—each underwent large clinical trials involving 
60 000–70 000 infants to detect a low risk of intussuscep-
tion. No elevated risk was found with either vaccine in the 
trials; both were subsequently recommended by WHO 
for global use starting in 2006.33
As millions of infants have been vaccinated in routine 
programmatic use, a low risk of ~1–5 excess intussus-
ception cases per 100 000 infants after the first dose of 
vaccine has been identified in postlicensure evaluations 
with both RotaTeq and Rotarix in several high- income 
and middle- income countries (figure 3).,3435,36,37,38,39,40 
However, given that the health benefits of rotavirus vacci-
nation greatly exceed this small risk, country and global 
policymakers continue to recommend routine use of 
rotavirus vaccines (table 1).41 Of note, an evaluation in 
seven African countries using Rotarix, the only data avail-
able to date from low- income countries, did not show any 
increased risk of intussusception.42 Similarly, in a separate 
evaluation in South Africa, no increased risk of intussus-
ception was observed after Rotarix vaccination.43 Given 
differences in intussusception epidemiology by region, 
additional data are needed to assess whether intussuscep-
tion risk varies by geographic and socioeconomic setting.
The biological mechanisms for the association between 
rotavirus vaccines and intussusception are not fully under-
stood. Studies in mice demonstrated that, despite the 
induction of intestinal lymphoid hyperplasia following 
wild- type rotavirus infection, lymphoid hyperplasia is 
not required as a lead point for rotavirus- induced intus-
susception.44 Mice studies also showed that changes in 
intestinal motility resulting from intestinal inflamma-
tion and cytokine induction may contribute to intussus-
ception, although how well these data apply to humans 
is unclear.45 Regardless of mechanism, the finding that 
intussusception risk appears greatest in the 3–7 days after 
administration of the first rotavirus vaccine dose suggest 
that it is related to intestinal replication of the orally 
Figure 3 Relative incidence of intussusception from self- controlled case- series analyses in the 1–7 days following dose 1 and 
dose 2 of rotavirus vaccine by country.
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administered live vaccine virus, which also peaks in the 
same interval after the first vaccine dose. This might also 
explain the apparent lack of intussusception risk seen in 
the African evaluations, as both the immune response to 
vaccination and levels of vaccine virus shedding in stools 
are substantially lower in infants from low- income and 
middle- income countries (LMICs) versus high- income 
countries.46
Although debated, some evidence suggested a 
potentially higher risk of intussusception among chil-
dren administered the first RotaShield dose at age >3 
months.4748 49 Because of this concern, age restrictions 
were initially recommended for rotavirus vaccines—the 
first dose to be administered no later than 15 weeks of age 
and the last dose no later than 32 weeks.50 However, these 
age restrictions could potentially disqualify a substantial 
number of children from receiving rotavirus vaccination, 
particularly in LMICs where delays in vaccine administra-
tion are common. Consequently, the risk–benefit of rota-
virus vaccination with and without age restrictions was 
re- examined. This analysis showed that, compared with an 
age- restricted schedule, rotavirus vaccination without age 
restrictions could prevent an additional 47 200 rotavirus 
deaths while potentially causing an additional 294 intus-
susception deaths in LMICs.51 Given these risk–benefit 
considerations, WHO recommended removal of age 
restrictions for rotavirus vaccination in LMICs, although 
administration of the first dose of rotavirus vaccine as 
soon as possible after 6 weeks of age is still recommended 
to maximise the net benefits of vaccination.29
Causality conclusion and areas for future research
Whether the short- term increased risk of intussusception 
immediately after vaccination translates into an overall 
population- level increase in intussusception is unknown. 
Some have hypothesised that vaccination may simply 
‘trigger’ intussusception earlier in some infants among 
whom intussusception would have occurred anyway 
later in infancy, and thus, there may be a compensatory 
decline later in life.52 Also, given that intussusception has 
been associated with three biologically different live- oral 
rotavirus vaccines, it has been hypothesised that wild- type 
rotavirus infection could be a cause of intussusception 
and vaccination may protect against rotavirus- induced 
intussusception.53 In the USA, population- level data post-
vaccine introduction do not show an overall increase 
in intussusception rates among infants despite a small 
increase in the 8–14 weeks age group when the first dose is 
administered.,5354 Furthermore, no long- term increased 
risk of intussusception in the year after vaccination was 
observed among rotavirus vaccinated vs unvaccinated 
infants; instead, a trend towards decreased long- term risk 
was seen.55 More data are needed to fully understand the 
overall population- level impact of rotavirus vaccination 
on intussusception risk.
In 2018, two new live- oral rotavirus vaccines—Rotavac 
(Bharat Biotech, Hyderabad, India) and Rotasiil (Serum 
Institute of India, Pune, India)—were prequalified by 
WHO. Prelicensure trials of these vaccines that included 
~5000 infants each were primarily designed to examine 
vaccine efficacy.565758 Consequently, as larger numbers 
of infants are immunised with these vaccine in different 
geographical locations, generating post- licensure intus-
susception data for these vaccines is a priority.
HPV VACCINE AND POTS AND CRPS
HPV vaccines are powerful tools for preventing cervical 
cancers and other HPV- related diseases worldwide. Three 
HPV vaccines are licensed: bivalent (2vHPV, Cervarix), 
quadrivalent (4vHPV, Gardasil) and 9- valent vaccines 
(9vHPV, Gardasil-9). Since 2006, HPV vaccines have 
been licensed in over 90 countries.59 Substantial reas-
suring vaccine safety data have been accumulated from 
pre- licensure trials as well as postlicensure monitoring 
and evaluations.60 Syncope and anaphylaxis are known, 
Table 1 Risk–benefit of rotavirus vaccination by country on rotavirus hospitalisations and deaths and associated 


















Australia35 Rotarix Doses 1 and 2 4.3 Hospitalisations: 6528
Deaths: not reported
Hospitalisations: 14
Deaths: not reportedRotaTeq Doses 1 and 2 7.0
USA36 39 Rotarix Doses 1 and 2 5.3 Hospitalisations: 53 444
Deaths: 14
Hospitalisations: 35–166
Deaths: 0.1–0.5Dose 2 only 7.3
RotaTeq Dose 1 only 0.7–1.5 Not reported Not reported




Note: Table adapted from Reference.87
*Excess intussusception cases per 100 000 vaccinated infants.
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rare adverse events following HPV vaccination. Despite 
a favourable safety profile, concerns about safety have 
impacted the acceptability of HPV vaccines in some 
countries. A variety of safety concerns have been raised 
and investigated for HPV vaccine; two safety concerns 
include CRPS and POTS. Both syndromes have created 
challenges for national immunisation programmes, 
especially in Japan, Denmark and Ireland, resulting in 
decreased public confidence, decreased coverage rates 
and/or withdrawal of national HPV vaccination recom-
mendations.61
The biological mechanisms of CRPS and POTS are not 
well understood. CRPS is a rare chronic pain disorder 
that affects one part of the body and is disproportionate 
to the intensity of any injury or tissue damage.61 It is typi-
cally precipitated by trauma, exposure or illness causing 
nerve or tissue injury and is commonly associated with 
autonomic nervous dysfunction.62 POTS is a form of 
dysautonomia that is characterised by orthostatic intol-
erance and often accompanied by a range of other symp-
toms, including headache, other aches and pain, fatigue 
and nausea.62 Both CRPS and POTS are diagnostically 
challenging syndromes with unclear heterogeneous aeti-
ology and onset. While the two syndromes are clinically 
distinct, symptoms often overlap with each other and 
with other conditions, such as chronic fatigue syndrome 
and fibromyalgia. Both are known to occur in adoles-
cence and early adulthood.63 Estimated incidence rates 
for CRPS and POTS are 6.28 per 100 000 person- years 
and 10.1 per 100 000 person- years, respectively.64
Published case reports of these syndromes following 
HPV vaccination have garnered media attention, 
contributing to public concern about HPV vaccination. 
Efforts to describe dysautonomia symptoms following 
HPV vaccination have included studies with small 
samples and some have included cases recruited from 
clinics that evaluate persons with an existing concern of 
HPV vaccine- induced illness or online sites discussing 
HPV vaccine injury.656667 The generalisability and validity 
of these studies are unknown. Few data are available 
from large population- based studies. Two large US data 
mining studies did not identify any signals for CRPS or 
POTS.,6869 Monitoring from the US Vaccine Adverse 
Event Reporting System found few reports of CRPS or 
POTS and no patterns to suggest a causal association 
with either Cervarix, Gardasil, or Gardasil-9.707172 An 
extensive review of GlaxoSmithKline’s safety database for 
CRPS following Cervarix also did not find an increase in 
the incidence of CRPS following vaccination.73 In 2015, 
the EMA conducted a detailed expert review of CRPS 
and POTS following HPV vaccines from a variety of 
data sources and concluded that the available evidence 
does not support that CRPS or POTS are caused by HPV 
vaccine.74 In 2017, after a review of available data, WHO’s 
GACVS found no new evidence for a causal association 
between HPV vaccines and CRPS and POTS.75 More 
recently, the American Autonomic Society published a 
position statement concluding that there are no data to 
support a causal relationship between HPV vaccination 
and CRPS and POTS.54
Causality conclusion and areas for future research
Despite the reassuring data available finding no associa-
tion between HPV vaccines and CRPS and POTS concerns 
continue to challenge immunisation programmes. Back-
ground rates in populations aged 9–26 years (the recom-
mended age group for HPV vaccine) would be helpful to 
determine if CRPS and POTS cases observed following 
HPV vaccination exceed what is expected. Quality 
population- based epidemiological studies with medical 
record validation can also serve as reliable resources 
to more convincingly evaluate whether HPV vaccina-
tion affects the risk of CRPS or POTS. Lastly, improved 
communication about vaccine safety is essential in main-
taining the public’s confidence in vaccines.
RTS,S/AS01 MALARIA VACCINE AND MENINGITIS, CEREBRAL 
MALARIA, FEMALE MORTALITY AND REBOUND SEVERE 
MALARIA
RTS,S/AS01E is a recombinant yeast- expressed subunit 
malaria vaccine using the hepatitis B surface antigen 
as a matrix carrier for epitopes derived from the Plas-
modium falciparum circumsporozoite protein formu-
lated with a proprietary AS01E. The phase 3 trial of the 
vaccine included ~9000 children aged 5–17 months and 
6500 infants aged 6–12 weeks, enrolled at 11 centres in 
seven countries in sub- Saharan Africa. Participants were 
randomly assigned (1:1:1) at first vaccination to receive 
three doses of RTS,S/AS01E at months 0, 1, 2 and 20; 
three doses of RTS,S/AS01E and a dose of comparator 
vaccine at month 20; or a comparator vaccine at months 
0, 1, 2 and 20. Cases of clinical and severe malaria were 
captured through passive surveillance and any serious 
adverse events were also recorded. Children were 
followed up for at least 3 years after the first vaccine 
dose.76 The vaccine was efficacious against clinical 
malaria in both age groups but had higher efficacy in the 
older age group. Protection was relatively high after the 
first vaccine course but declined with time since vacci-
nation, with little residual protection two or more years 
after vaccination. Protection was boosted by the fourth 
vaccine dose but protection against severe malaria over 
the whole trial period was demonstrated only in the older 
age group among children who received four vaccine 
doses.
Following the trial, the EMA gave the vaccine a positive 
scientific opinion77 and the two WHO policy committees 
on vaccination and malaria (SAGE and Malaria Policy 
Advisory Committee, MPAC, respectively) recommended 
pilot implementation studies in children from the age 
of 5 months. These were started in Malawi, Ghana and 
Kenya in 2019.78
Safety concerns arising from the phase 3 trial
Meningitis: Among children in the older age group, there 
was an excess of cases of meningitis in those who received 
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RTS,S/AS01E (with or without a fourth dose) compared 
with the control group (10, 11 and 1 case, respectively). 
An excess was not observed in the younger age group 
(6, 7 and 6 cases, respectively). The cases showed no 
temporal association with vaccination and included a 
mixture of aetiologies. Most cases were reported from 
two trial sites.79 GACVS concluded that meningitis should 
be regarded as a potential signal which requires further 
assessment postlicensure.80
Cerebral malaria: In the older age group, there was 
an excess of cerebral malaria in the 4 and 3 dose groups 
compared with the control group (19, 24 and 10 cases, 
respectively). Cases showed no clustering with respect 
to dates of vaccination and no excess was seen in the 
younger age group (6, 7 and 7 cases, respectively).
Female mortality: Mortality was not a primary endpoint 
in the phase 3 trial as it was expected (and observed)81 
that this would be low in a carefully monitored trial. In 
the older age group, overall mortality was higher in the 
two vaccinated groups than in the control group (112 
deaths vs 46 (2:1 ratio)) but not significantly so, and the 
same was true in the younger age group (105 deaths vs 
42 (2:1 ratio)). However, in a post hoc analysis, while 
boys mortality rates were lower among those vaccinated 
than in the control group (older age group 1.5% vs 2.0%; 
younger age group 2.2% vs 2.4%), girls mortality rates 
were higher among those vaccinated (older age group 
2.3% vs 1.1%; younger age group 2.6% vs 1.5%).82 There 
was no explanatory pattern for the gender imbalances 
among causes of death ascertained by verbal autopsies.67
Rebound malaria: In the older age group there was a 
reduced risk of severe malaria between the first vaccine 
course (three doses) and the time of the fourth dose. 
After the fourth dose, the rate of severe malaria was 
similar to that in the control group. However, in those 
who received only three doses, after 18 months the inci-
dence of severe malaria was higher than in the control 
group, and over the whole trial period the incidence of 
severe malaria was similar in the three- dose group as in 
the control group. This raised two potential longer- term 
safety concerns. First that the incidence of severe malaria 
in the three- dose group would exceed that in the control 
group in the longer term and, second, that there may be 
a similar ‘rebound’ in the four- dose group after a longer 
time interval. However, no evidence of these potential 
effects was seen in a study in which children in the trial 
from a subset of 3 trial sites were followed up for 7 years 
postvaccination.83
Causality conclusion and areas for future research
RTS,S/AS01 was reviewed comprehensively by the EMA, 
and although they are not empowered to licence a vaccine 
that is not intended for use in the European Union, 
the ‘positive scientific opinion’ they gave indicated that 
the vaccine satisfied the criteria for licensure.84 Gener-
ally, when a vaccine has been licensed, potential safety 
concerns would be addressed through the manufacturers 
postmarketing risk management. The recommendation 
from SAGE and MPAC for pilot implementation studies 
before more widespread use was a novel approach.85 
As well as assessing impact and delivery feasibility in 
programmatic conditions, the pilot studies have been 
powered to address the safety concerns related to menin-
gitis, cerebral malaria and gender- specific mortality.86
Except for the possibility of rebound malaria, there 
are no clear biological mechanisms to explain any of the 
other safety signals observed and the possibility that they 
were chance findings cannot be excluded.
Evaluation by regulators and investigators of data gath-
ered in the pilot studies in the three implementing coun-
tries will be key to the risk–benefit assessment for the 
eventual expanded use of RTS,S/AS01E in vaccination 
programmes in sub- Saharan Africa.
CONCLUSIONS
Lessons learnt for vaccine safety in genreal and opportu-
nities for future reserarech
Vaccine safety science must be proactive and timely, 
and conducted with rigour, objectivity and transparency. 
Vaccine safety concerns are often for outcomes that seem 
to be increasing in incidence, have poorly understood 
aetiology and are concerning to the public. When new 
or unexpected adverse events following immunisation 
(AEFI) occur, it is helpful to have case definitions already 
available or quickly developed. Poor understanding of 
disease aetiology and limitations in disease diagnostics 
hamper vaccine safety studies as exemplified by POTS 
and CRPS. Such diseases often end up with rapid consul-
tations from experts not typically engaged in vaccine 
safety monitoring. It is important to have mechanisms in 
place to rapidly engage expertise in the AEFI of interest. 
The HPV/POTS- CRPS situation also exemplifies the 
importance of rigorous and timely studies. Quality 
population- based epidemiological studies with medical 
record outcome validation would provide far more 
conclusive evidence than we currently have, yet several 
countries have already experienced drops in immuni-
sation coverage because of these issues. Good science 
takes time, whereas anecdotes and misinformation 
spread quickly. It is advisable for vaccine safety science to 
inform the public’s views, rather than try to change views 
that have already been formed. Strong infrastructure, 
adequate funding and a willingness to address public 
concerns from the scientific community can improve 
the timelines of rigorous safety science and its ability to 
impact public views and vaccination decisions.
Most AEFIs that are causally linked with vaccination 
occur within a few weeks after vaccination (eg, narcolepsy 
following pandemic influenza vaccination, intussuscep-
tion following rotavirus vaccination). Such temporal asso-
ciations tend to suggest plausibility of causal associations, 
but there are important caveats. First, in passive surveil-
lance systems, AEFIs purported to be related to vaccina-
tion are most likely to be reported if they occur close to 
the time of vaccination. Events occurring more distant 
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from vaccination may not be reported, even if they are 
truly causally related. Temporal association may be falsely 
interpreted as causal, particularly for health outcomes 
that vary in incidence with age if an age group with a 
high incidence happens to be around the age at which a 
vaccine is introduced.
AEFIs that occur with no clear temporal relationship 
to vaccination are difficult to assess, because most surveil-
lance systems for AEFIs are not set up to detect such 
associations. For example, the increased risk of severe 
dengue in seronegative vaccinees only became apparent 
in the third year after vaccination. Some vaccinations 
increase the susceptibility to adverse events from other 
exposures that may occur any time after vaccination. 
This seems to be the only plausible mechanism for the 
possible increased risk of meningitis following RTSS/
AS01E. More research is needed on the long- term effects 
of vaccinations, both beneficial and detrimental, beyond 
their effects on the target disease. Proving a negative is 
difficult (eg, the HPV vaccine associations, the trials of 
second- generation rotavirus vaccines) and consequently 
upper limits on the possible risk must be defined. Vaccine 
safety research is often difficult, and requires substantial 
resources. Without regulatory requirements, manufac-
turers may not be incentivised to do so. Who pays for such 
research and how it gets done remains an outstanding 
question. This is particularly challenging in LMICs which 
lack the infrastructure for vaccine safety studies.
Often in vaccine safety science, there is too great a 
focus on relative risks, rather than vaccine- attributable 
risks, which may heighten fears about rare events (eg, 
intussusception following rotavirus vaccine). Relative 
risks are important for determining the causal association 
of an AEFI. However, from a public health perspective 
attributable risks to the vaccine are of primary interest, 
so proper comparisons can be made to the risks of a 
vaccine preventable disease and the benefits of vaccina-
tion. Vaccine risk must be viewed alongside the benefits, 
and the risk- benefit ratio may vary (eg, between high and 
LMICs) as is the case with intussusception and rotavirus 
vaccines.
Interactions between the vaccine, natural disease and 
the AEFI are particularly difficult to identify and sepa-
rate the effect of disease vs the vaccine. In- depth under-
standing of natural disease facilitates understanding the 
interaction between the vaccine and natural disease. 
Attention to these interactions between natural disease 
and the vaccine may be explored through vaccine devel-
opment and clinical trials or studied for safety in popula-
tions with a low burden of natural disease.
The case studies presented herein elucidate opportuni-
ties for future research. These case studies were selected 
because they are recent and varied in the vaccine safety 
issues they elucidate. However, a systematic review of 
vaccine safety would facilitate development of a global 
vaccine safety research agenda, which would be incred-
ibly useful. Consideration should be given to scientific 
uncertainties, public concerns, how many people are 
exposed to the vaccine, and the frequency and severity of 
the AEFI to facilitate prioritisation. The research agenda 
should then be used to rapidly and rigorously investigate 
high priority research.
Communication around vaccine safety must be proac-
tive and timely, evidence- based, finding commonalities 
with the public through shared values, tailored to indi-
viduals and from credible sources. One vaccine safety 
issue can spill over to other vaccines and adversely impact 
routine vaccination programmes. Communication must 
address the specific issues at hand, but also consider the 
broader issues of vaccine benefits and confidence in 
immunisation programmes.
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